Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Vaxcyte (PCVX) Leases (2021 - 2026)

Vaxcyte (PCVX) has 6 years of Leases data on record, last reported at $113.1 million in Q1 2026.

  • On a quarterly basis, Leases rose 28.88% to $113.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $113.1 million, a 28.88% increase, with the full-year FY2025 number at $116.0 million, up 60.9% from a year prior.
  • Leases reached $113.1 million in Q1 2026 per PCVX's latest filing, down from $116.0 million in the prior quarter.
  • Over the last five years, Leases for PCVX hit a ceiling of $116.0 million in Q4 2025 and a floor of $16.3 million in Q3 2023.
  • A 5-year average of $48.8 million and a median of $28.7 million in 2024 define the central range for Leases.
  • Peak YoY movement for Leases: soared 7355.05% in 2022, then fell 28.64% in 2023.
  • Tracing PCVX's Leases over 5 years: stood at $28.4 million in 2022, then increased by 9.14% to $31.0 million in 2023, then surged by 132.61% to $72.1 million in 2024, then soared by 60.9% to $116.0 million in 2025, then dropped by 2.5% to $113.1 million in 2026.
  • Business Quant data shows Leases for PCVX at $113.1 million in Q1 2026, $116.0 million in Q4 2025, and $83.5 million in Q3 2025.